Enrollment begins in Pharmaxis phase 3 trial of Bronchitol for lung disease

By Lisa Kerner

Erie, Pa., April 19 - Pharmaxis Ltd. said it has enrolled the first of 350 patients in its phase 3 trial of Bronchitol to treat bronchiestasis, an incurable, chronic obstructive lung disease affecting more than 500,000 people worldwide.

Enrollment should take eight months, with results as early as June 2007.

The four-month trial will be conducted at 22 centers in Australia, New Zealand, Northern Ireland and the United States. Two-thirds of the patients will receive Bronchitol twice daily, with the remaining 1/3 receiving a placebo.

All patients will be assessed for mucous clearance and quality of life, measured by symptoms, cough severity, exercise capacity and lung function, according to a news release.

Bronchitol, an inhalable dry powder administered by a pocket-sized device, received orphan drug status in 2005.

Pharmaxis is a specialty pharmaceutical company located in Sydney, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.